Parathyroid hormone receptor 1(pth1r) antibodies and uses thereof
AssigneeXoma (US) LLC
InventorsRaphael D. Levy, Hassan Issafras, Agnes Choppin Holmes, Kirk W. Johnson, Amer M. Mirza, Daniel H. Bedinger, Rachel A. Hunt, Toshihiko Takeuchi, Kiranjit Kaur Ahluwalia, Robyn Cotter
Life of this patent
Estimating the term…
Abstract
The present disclosure relates, in general, human antibodies against human parathyroid hormone receptor 1 (PTH1R) and methods of use of such antibodies in the treatment of cancer, Humoral Hypercalcemia of Malignancy (HHM), or Primary Hyperparathyroidism (PHPT) and Secondary Hyperparathyroidism (SHPT) and cachexia.
Claims48
An antibody that binds parathyroid hormone receptor 1 (PTH1R) with an affinity Kd of 2×10−8 M or less.
3-4. (canceled)
(canceled)
An antibody that binds parathyroid hormone receptor 1 (PTH1R) comprising (a) a heavy chain CDR1 amino acid sequence set forth in SEQ ID NOs:
- 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 102, or a variant thereof in which one or two amino acids have been changed;
- (b) a heavy chain CDR2 amino acid sequence set forth in SEQ ID NOs:
- 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 73, 76, 79, 82, 85, 88, 91, 94, 97, 100, 103 that is from the same heavy chain variable region as (a), or a variant thereof in which one or two amino acids have been changed;
- and
- (c) a heavy chain CDR3 amino acid sequence set forth SEQ ID NOs:
- 29, 32, 35, 38, 41, 44, 47, 50, 53, 56, 59, 62, 65, 68, 71, 74, 77, 80, 83, 86, 89, 92, 95, 98, 101, 104 that is from the same heavy chain variable region as (a), or a variant thereof in which one or two amino acids have been changed.
11-14. (canceled)
(canceled)
19-21. (canceled)
23-25. (canceled)
27-29. (canceled)
An antibody that binds parathyroid hormone receptor 1 (PTH1R) comprising a light chain variable region and/or a heavy chain variable region, wherein
- (a) the light chain variable region comprises at least a CDR1 selected from SEQ ID NOs:
- 131, 134, 137, 140, 143, 146, 149, 152, 155, 158, 161, 164, 167, 170, 173, 176, 179, 182, 185, 188, 191, 194, 197, 200, 203, 206 or sequences at least 80% identical thereto, a CDR2 selected from SEQ ID NOs:
- 132, 135, 138, 141, 144, 147, 150, 153, 156, 159, 162, 165, 168, 171, 174, 177,180, 183, 186, 189, 192,195, 198, 201, 204, 207 or sequences at least 80% identical thereto, and/or a CDR3 selected from SEQ ID NOs:
- 133, 136, 139, 142, 145, 148, 151, 154, 157,160, 163, 166, 169, 172,175, 178, 181, 184, 187, 190, 193, 196, 199, 202, 205, 208 or sequences at least 80% identical thereto;
- and/or wherein
- (b) the heavy chain variable region comprises at least a CDR1 selected from SEQ ID NOs:
- 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 102 or sequences at least 80% identical thereto, a CDR2 selected from SEQ ID NOs:
- 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 73, 76, 79, 82, 85, 88, 91, 94, 97, 100, 103 or sequences at least 80% identical thereto, and/or a CDR3 selected from SEQ ID NOs:
- 29, 32, 35, 38, 41, 44, 47, 50, 53, 56, 59, 62, 65, 68, 71, 74, 77, 80, 83, 86, 89, 92, 95, 98, 101, 104 or sequences at least 80% identical thereto.
32-33. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
59-60. (canceled)
Dependencies are inferred from the claim text.